HEADACHE is a premier academic journal dedicated to advancing the study of headache disorders through innovative research and clinical insights. Published by WILEY, this influential journal has been serving the neurology community since its inception in 1961 and is recognized as a leader in its field, boasting an impressive Q1 ranking in both Neurology and Neurology (clinical) categories for 2023. With a robust Scopus ranking of #48 in clinical neurology and #26 in neuroscience, HEADACHE consistently publishes high-quality research that contributes to the understanding and treatment of headache disorders worldwide. Although it does not offer open access options, the journal remains accessible to a wide audience through various institutional subscriptions. It aims to provide a platform for researchers, healthcare professionals, and students to exchange ideas and develop new strategies for headache management, making it an essential resource for those dedicated to improving patient outcomes in this challenging area of healthcare.

Epilepsy Currents, published by SAGE Publications Inc, is a vital scholarly journal dedicated to the field of neurology, specifically focusing on epilepsy and seizure-related disorders. With its ISSN 1535-7597 and E-ISSN 1535-7511, the journal aims to disseminate high-quality research, reviews, and clinical insights that contribute to the understanding and management of epilepsy. Boasting a Q3 ranking in clinical neurology for the year 2023, it is positioned among the noteworthy academic resources available to professionals and researchers alike, with its Scopus rank placing it within the 36th percentile of its category. Despite its current non-open access status, the journal remains an essential repository of knowledge for those looking to deepen their expertise in neurology and to stay abreast of the latest developments in the field. Operating out of Thousand Oaks, California, Epilepsy Currents emphasizes evidence-based practices and innovative approaches, encouraging an active dialogue within the academic community and ensuring its ongoing relevance as it converges from 2011 to 2024.

The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

Schizophrenia Research is a premier academic journal focused on innovative research within the domain of psychiatry and mental health, published by Elsevier. With its ISSN 0920-9964 and E-ISSN 1573-2509, the journal has established a strong presence since its inception in 1988, evolving to publish cutting-edge findings up to 2024. Positioned in Q1 in Psychiatry and Mental Health and Q2 in Biological Psychiatry, it ranks impressively in the 83rd percentile among its peers, according to Scopus, ranking #93/567 in the field of Medicine, and #12/51 in Neuroscience. This journal serves as a vital platform for the dissemination of significant scientific advancements and theoretical insights into schizophrenia, fostering a deeper understanding of mental illnesses. Although it operates on a subscription basis, its critical role in informing both ongoing research and clinical practices cannot be overstated, making it an essential resource for researchers, clinicians, and students alike. Join a global community dedicated to improving mental health outcomes and advancing the study of schizophrenia through this reputable publication.

Schizophrenia, published by NATURE PORTFOLIO, is a pioneering open-access journal established in 2022, dedicated to advancing the scientific understanding of schizophrenia and its associated disorders. With its commitment to disseminating high-quality research without barriers, this journal aims to provide a platform for innovative studies, reviews, and meta-analyses that enhance clinical practices and therapeutic approaches. The journal is strategically located in Berlin, Germany, a hub for mental health research and innovation. By facilitating open exchange among researchers, professionals, and students, Schizophrenia aspires to be at the forefront of the global discourse on psychiatric disorders, driving forward critical advancements that can translate into improved patient care and outcomes. With a focus on promoting the latest findings in epidemiology, neurobiology, pharmacology, and psychosocial interventions, this journal is poised to become an essential resource for scholars and practitioners alike, eager to make significant contributions to the field.

Archives of Epilepsy is a pioneering academic journal dedicated to advancing the field of epilepsy research and clinical practice. Published by GALENOS PUBL HOUSE in Turkey, this Open Access journal has embraced the principle of unrestricted access since its inception in 2012, allowing researchers, healthcare professionals, and students from around the world to engage with cutting-edge findings in neuropathology. With a focus on clinical and neuroscience aspects of neurology, the journal occupies a significant position in the academic landscape, currently ranked in the Q4 quartile in both Neurology and Clinical Neurology categories as of 2023. Though it faces challenges in its Scopus rankings with a current percentile of 2nd in Medicine - Neurology (Clinical) and 1st in Neuroscience - Neurology, it offers a valuable platform for emerging studies. The journal's commitment to fostering a comprehensive understanding of epilepsy is crucial, as it facilitates broader discourse on effective treatments and patient care strategies. We invite researchers and practitioners to explore the impactful articles published in the Archives of Epilepsy and contribute to an evolving dialogue that strives to improve outcomes for individuals affected by epilepsy.

EPILEPSIA is a premier academic journal published by Wiley, with a storied history dating back to 1909, making it a cornerstone in the field of epilepsy research and neurology. With an impressive impact factor reflecting its robust contribution to the academic community, EPILEPSIA is categorized in the top quartile (Q1) in both neurology and clinical neurology as of 2023, underscoring its significance and prestige. The journal is ranked #15 out of 192 in Neuroscience & Neurology and #34 out of 400 in Medicine & Neurology (clinical) within Scopus, indicating its essential role in advancing knowledge and treatments related to epilepsy. Researchers and clinicians are encouraged to contribute groundbreaking studies, case reports, and reviews that inform best practices and improve patient outcomes. Although EPILEPSIA currently does not offer open access options, its detailed exploration of both fundamental and clinical aspects of epilepsy ensures wide dissemination of crucial findings among professionals and students alike, furthering the understanding and management of this complex condition.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.